Manish Narang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Manish Narang has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Sunil Gomber
Univ Delhi, Pediat, Univ Coll Med Sci, Delhi, ON, Canada
7 shared publicationsAmarender Singh Puri
GB Pant Institute of PGMER
4 shared publications- Mohammad Moonis Akbar Faridi
Department of Pediatrics, Era’s Lucknow Medical College and Hospital, Lucknow 22600, India
4 shared publications Dheeraj Shah
University of Delhi
3 shared publications- Dheeraj Shah
Department of Pediatrics and Medical Education, University College of Medical Sciences, New Delhi, India
3 shared publications - Kamal Thammireddy
Biological E. Limited, Hyderabad 500033, India
3 shared publications
Latest Publications
- Open Access
Association Between Pre-Existing Anti-Diphtheria Toxoid IgG and Immune Responses to a CRM197-Conjugated 14-Valent Pneumococcal Conjugate Vaccine in Infants: A Post Hoc Analysis of a Multicenter Phase III Trial
Background/Objectives: Maternally transferred antibodies protect infants early in life, but high concentrations can reduce immune responses to primary vaccination. CRM197 is a nontoxic mutant of diphtheria toxin that retains antigenic similarity to the native protein. We therefore investigated whether anti-diphtheria antibodies present before vaccination were related to responses against pneumococcal polysaccharides conjugated to CRM197. Methods: This post hoc analysis used data from a multicenter, randomized, single-blind phase III trial in which Indian infants received BE-PCV14/PNEUBEVAX 14® at 6–8, 10–12, and 14–16 weeks of age (commonly referred to as 6–10–14 weeks). Baseline anti-diphtheria toxoid IgG concentrations measured at 6–8 weeks were assessed in relation to serotype-specific pneumococcal IgG responses 28 days after dose 3. We evaluated these associations using categorical and continuous analyses with false-discovery-rate correction for serotype-specific comparisons. Results: Baseline and post-primary results were available for 603 of 650 infants in the co-administration cohort. Post-primary pneumococcal IgG concentrations did not differ significantly across the baseline anti-diphtheria IgG categories. Individual fold rises differed nominally among baseline anti-diphtheria IgG categories for serotype 5, but the difference did not remain significant after multiplicity correction. In the adjusted continuous models, geometric mean ratios (GMRs) associated with each 2-fold increase in baseline anti-diphtheria IgG ranged from 0.978 to 1.011, with no statistically significant associations after false-discovery-rate correction. Analyses stratified by baseline pneumococcal IgG similarly showed no consistent evidence of reduced responses. Conclusions: In this cohort, pre-existing anti-diphtheria toxoid IgG measured before vaccination, which was likely maternally derived, was not associated with a consistent reduction in post-primary serotype-specific pneumococcal IgG responses to CRM197-conjugated BE-PCV14.
Open AccessAssociation Between Pre-Existing Anti-Diphtheria Toxoid IgG and Immune Responses to a CRM197-Conjugated 14-Valent Pneumococcal Conjugate Vaccine in Infants: A Post Hoc Analysis of a Multicenter Phase III Trial
Background/Objectives: Maternally transferred antibodies protect infants early in life, but high concentrations can reduce immune responses to primary vaccination. CRM197 is a nontoxic mutant of diphtheria toxin that retains antigenic similarity to the native protein. We therefore investigated whether anti-diphtheria antibodies present before vaccination were related to responses against pneumococcal polysaccharides conjugated to CRM197. Methods: This post hoc analysis used data from a multicenter, randomized, single-blind phase III trial in which Indian infants received BE-PCV14/PNEUBEVAX 14® at 6–8, 10–12, and 14–16 weeks of age (commonly referred to as 6–10–14 weeks). Baseline anti-diphtheria toxoid IgG concentrations measured at 6–8 weeks were assessed in relation to serotype-specific pneumococcal IgG responses 28 days after dose 3. We evaluated these associations using categorical and continuous analyses with false-discovery-rate correction for serotype-specific comparisons. Results: Baseline and post-primary results were available for 603 of 650 infants in the co-administration cohort. Post-primary pneumococcal IgG concentrations did not differ significantly across the baseline anti-diphtheria IgG categories. Individual fold rises differed nominally among baseline anti-diphtheria IgG categories for serotype 5, but the difference did not remain significant after multiplicity correction. In the adjusted continuous models, geometric mean ratios (GMRs) associated with each 2-fold increase in baseline anti-diphtheria IgG ranged from 0.978 to 1.011, with no statistically significant associations after false-discovery-rate correction. Analyses stratified by baseline pneumococcal IgG similarly showed no consistent evidence of reduced responses. Conclusions: In this cohort, pre-existing anti-diphtheria toxoid IgG measured before vaccination, which was likely maternally derived, was not associated with a consistent reduction in post-primary serotype-specific pneumococcal IgG responses to CRM197-conjugated BE-PCV14.
- Open Access
Safety, Immunogenicity of Co-Administered Vaccines, and Lot-to-Lot Consistency of a 14-Valent Pneumococcal Conjugate Vaccine (PNEUBEVAX 14®) Administered at 6–10–14 Weeks in Healthy Infants: A Multicenter, Phase IV Trial
Background: Pneumococcal conjugate vaccines (PCVs) have substantially reduced pneumococcal disease in children; however, serotype distribution varies geographically, and residual disease due to non-PCV13 serotypes persists. Biological E’s PNEUBEVAX 14® (BE-PCV14), a WHO-prequalified 14-valent PCV, expands coverage by including serotypes 22F and 33F. As PCVs are co-administered with routine Expanded Programme on Immunization (EPI) vaccines, post-licensure data on safety, co-administration, and lot-to-lot consistency are essential. This multicenter phase IV study evaluated BE-PCV14 in healthy PCV-naïve infants aged 6–8 weeks across 31 sites in India. Methods: A total of 2600 infants were enrolled and vaccinated at 6, 10, and 14 weeks of age; 2300 received BE-PCV14 and 300 received PCV13. All participants received concomitant DTwP-HepB-IPV-Hib and oral rotavirus vaccines per routine schedule. Safety was assessed through solicited and unsolicited adverse events (AEs) and serious adverse events (SAEs). Immunogenicity subsets evaluated responses to co-administered vaccines and serotype-specific responses across three BE-PCV14 lots. Results: Among 2600 vaccinated infants, at least one AE occurred in 26.35% (95% CI: 24.59, 28.19) of BE-PCV14 and 24.67% (95% CI: 20.13, 29.84) of PCV13 recipients; most were mild. Injection-site pain and pyrexia were the most common events. Immune responses to co-administered vaccines were comparable between groups and met the non-inferiority criteria: lower bound of the two-sided 95% CI > −10 percentage points for seroprotection/seroconversion rate differences using the Farrington–Manning method. Lot-to-lot consistency was demonstrated, with all GMC ratios within the predefined equivalence margin (0.5–2.0). Conclusions : BE-PCV14 was well tolerated. Immune responses to co-administered routine EPI vaccines met predefined non-inferiority criteria, supporting the interpretation that BE-PCV14 did not result in clinically meaningful immune interference. Consistent immune responses across manufacturing lots further support its use in infant immunization programs.
Open AccessSafety, Immunogenicity of Co-Administered Vaccines, and Lot-to-Lot Consistency of a 14-Valent Pneumococcal Conjugate Vaccine (PNEUBEVAX 14®) Administered at 6–10–14 Weeks in Healthy Infants: A Multicenter, Phase IV Trial
Background: Pneumococcal conjugate vaccines (PCVs) have substantially reduced pneumococcal disease in children; however, serotype distribution varies geographically, and residual disease due to non-PCV13 serotypes persists. Biological E’s PNEUBEVAX 14® (BE-PCV14), a WHO-prequalified 14-valent PCV, expands coverage by including serotypes 22F and 33F. As PCVs are co-administered with routine Expanded Programme on Immunization (EPI) vaccines, post-licensure data on safety, co-administration, and lot-to-lot consistency are essential. This multicenter phase IV study evaluated BE-PCV14 in healthy PCV-naïve infants aged 6–8 weeks across 31 sites in India. Methods: A total of 2600 infants were enrolled and vaccinated at 6, 10, and 14 weeks of age; 2300 received BE-PCV14 and 300 received PCV13. All participants received concomitant DTwP-HepB-IPV-Hib and oral rotavirus vaccines per routine schedule. Safety was assessed through solicited and unsolicited adverse events (AEs) and serious adverse events (SAEs). Immunogenicity subsets evaluated responses to co-administered vaccines and serotype-specific responses across three BE-PCV14 lots. Results: Among 2600 vaccinated infants, at least one AE occurred in 26.35% (95% CI: 24.59, 28.19) of BE-PCV14 and 24.67% (95% CI: 20.13, 29.84) of PCV13 recipients; most were mild. Injection-site pain and pyrexia were the most common events. Immune responses to co-administered vaccines were comparable between groups and met the non-inferiority criteria: lower bound of the two-sided 95% CI > −10 percentage points for seroprotection/seroconversion rate differences using the Farrington–Manning method. Lot-to-lot consistency was demonstrated, with all GMC ratios within the predefined equivalence margin (0.5–2.0). Conclusions : BE-PCV14 was well tolerated. Immune responses to co-administered routine EPI vaccines met predefined non-inferiority criteria, supporting the interpretation that BE-PCV14 did not result in clinically meaningful immune interference. Consistent immune responses across manufacturing lots further support its use in infant immunization programs.
- 27 March 2026
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 31 (4) , 360-366
Proteinuria and gall bladder wall thickness as predictive indicators for dengue severity in pediatric patients
Objectives: Dengue is a mosquito-borne viral illness affecting children and can progress to severe forms with capillary leakage, bleeding and organ dysfunction. Early detection is crucial to reduce complications. This study evaluated the predictive value of 2 noninvasive markers, urine albumin-creatinine ratio (UACR) and gall bladder wall thickness (GBWT) for disease severity in pediatric dengue. Methods: A prospective observational study was conducted from May 2023 to November 2024 at a tertiary care hospital in Northern India. Children aged 6 months to 12 years with moderate to severe dengue (WHO 2009 classification) were included. UACR was measured from spot urine samples at admission, during deterioration or at discharge. GBWT was assessed via abdominal ultrasound between days 3 and 6 of fever. Associations with disease severity, laboratory parameters, and mortality outcomes were analyzed. Results: Among 74 participants, mean UACR (mg/g) was significantly higher in severe dengue compared to moderate cases (136.31 [151.26] vs. 44.87 [59.77]; P < 0.001), with elevated UACR linked to higher mortality. Mean GBWT (mm) was significantly greater in severe dengue (7.35 [2.25] vs. 5.11 [2.49]; P = 0.035), correlating with poor outcomes. Sensitivity and specificity of UACR (cutoff 30 mg/g) were 62% and 60%, and GBWT at 5 mm were 81% and 60%. Odds ratios for severe dengue were 3.9 (UACR), 10.7 (GBWT) and 13.3 (both). Honeycomb GBWT patterns were more frequent in fatal cases. Conclusion: UACR and GBWT, while not definitive alone, are noninvasive adjuncts for predicting severity and mortality in pediatric dengue, supporting early identification, triage and management.
- 27 March 2026
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 31 (4) , 360-366
Proteinuria and gall bladder wall thickness as predictive indicators for dengue severity in pediatric patients
Objectives: Dengue is a mosquito-borne viral illness affecting children and can progress to severe forms with capillary leakage, bleeding and organ dysfunction. Early detection is crucial to reduce complications. This study evaluated the predictive value of 2 noninvasive markers, urine albumin-creatinine ratio (UACR) and gall bladder wall thickness (GBWT) for disease severity in pediatric dengue. Methods: A prospective observational study was conducted from May 2023 to November 2024 at a tertiary care hospital in Northern India. Children aged 6 months to 12 years with moderate to severe dengue (WHO 2009 classification) were included. UACR was measured from spot urine samples at admission, during deterioration or at discharge. GBWT was assessed via abdominal ultrasound between days 3 and 6 of fever. Associations with disease severity, laboratory parameters, and mortality outcomes were analyzed. Results: Among 74 participants, mean UACR (mg/g) was significantly higher in severe dengue compared to moderate cases (136.31 [151.26] vs. 44.87 [59.77]; P < 0.001), with elevated UACR linked to higher mortality. Mean GBWT (mm) was significantly greater in severe dengue (7.35 [2.25] vs. 5.11 [2.49]; P = 0.035), correlating with poor outcomes. Sensitivity and specificity of UACR (cutoff 30 mg/g) were 62% and 60%, and GBWT at 5 mm were 81% and 60%. Odds ratios for severe dengue were 3.9 (UACR), 10.7 (GBWT) and 13.3 (both). Honeycomb GBWT patterns were more frequent in fatal cases. Conclusion: UACR and GBWT, while not definitive alone, are noninvasive adjuncts for predicting severity and mortality in pediatric dengue, supporting early identification, triage and management.
- Open Access
- 3 March 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 46
Immunogenicity and safety of Biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial
- 3 March 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 46
Open AccessImmunogenicity and safety of Biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial
- 24 August 2023
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (12) , 2070-2075
Ultrasound‐guided aspiration in addition to antibiotics for treatment of liver abscess in children: A randomized controlled trial
Background and Aim: The criteria for aspiration for pediatric liver abscess are unclear. In this randomized controlled trial, we evaluated the efficacy of ultrasound‐guided needle aspiration in addition to antibiotics in children with uncomplicated liver abscess.Methods: We enrolled 110 children aged 1–18 years (mean [SD] = 7.7 [3.7] years) with uncomplicated liver abscess. The primary outcome was clinical cure at 6 weeks (absence of fever and abdominal pain in the preceding 14 days with reduction in abscess size on ultrasonography). The secondary outcomes were clinical response at 4 weeks, fever resolution time, time to abdominal pain reduction and abdominal tenderness, duration of hospitalization, and treatment failure.Results: Clinical cure at 6 weeks was not significantly different (48/50 [96%] vs 39/46 [85%]; P = 0.082) between aspiration plus antibiotics group and antibiotics only group. The clinical response at 4 weeks was also comparable (49/50 [98%] vs 43/46 [93.5%]; P = 0.347). The mean (SD) of fever resolution time was significantly less in the aspiration plus antibiotics group (198 [90.8] h vs 248.2 [104.6] h; P = 0.014). Time to achieve reduction in abdominal pain (8.32 [3.1] vs 9.46 [3.1] days; P = 0.077) and abdominal tenderness (5.7 [2.4] vs 6.3 [2.3] days; P = 0.242), duration of hospitalization (16.6 [3.9] vs 18.2 [4.4] days; P = 0.07), and adverse event profile (9/50 [18%] vs 14/46 [30%]; P = 0.217) were comparable between the two groups.Conclusion: Majority of children with uncomplicated liver abscess achieved clinical cure at 6 weeks with intravenous antibiotics, irrespective of aspiration. However, needle aspiration may slightly reduce the duration of fever and abdominal pain/abdominal tenderness.
- 24 August 2023
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (12) , 2070-2075
Ultrasound‐guided aspiration in addition to antibiotics for treatment of liver abscess in children: A randomized controlled trial
Background and Aim: The criteria for aspiration for pediatric liver abscess are unclear. In this randomized controlled trial, we evaluated the efficacy of ultrasound‐guided needle aspiration in addition to antibiotics in children with uncomplicated liver abscess.Methods: We enrolled 110 children aged 1–18 years (mean [SD] = 7.7 [3.7] years) with uncomplicated liver abscess. The primary outcome was clinical cure at 6 weeks (absence of fever and abdominal pain in the preceding 14 days with reduction in abscess size on ultrasonography). The secondary outcomes were clinical response at 4 weeks, fever resolution time, time to abdominal pain reduction and abdominal tenderness, duration of hospitalization, and treatment failure.Results: Clinical cure at 6 weeks was not significantly different (48/50 [96%] vs 39/46 [85%]; P = 0.082) between aspiration plus antibiotics group and antibiotics only group. The clinical response at 4 weeks was also comparable (49/50 [98%] vs 43/46 [93.5%]; P = 0.347). The mean (SD) of fever resolution time was significantly less in the aspiration plus antibiotics group (198 [90.8] h vs 248.2 [104.6] h; P = 0.014). Time to achieve reduction in abdominal pain (8.32 [3.1] vs 9.46 [3.1] days; P = 0.077) and abdominal tenderness (5.7 [2.4] vs 6.3 [2.3] days; P = 0.242), duration of hospitalization (16.6 [3.9] vs 18.2 [4.4] days; P = 0.07), and adverse event profile (9/50 [18%] vs 14/46 [30%]; P = 0.217) were comparable between the two groups.Conclusion: Majority of children with uncomplicated liver abscess achieved clinical cure at 6 weeks with intravenous antibiotics, irrespective of aspiration. However, needle aspiration may slightly reduce the duration of fever and abdominal pain/abdominal tenderness.
- Open Access
- 29 May 2023
- Published by Springer Nature in Cureus
- Vol. 15 (5) , e39671
Serological Response to COVID-19 and Its Association With Measles-Rubella (MR)-Containing Vaccines
Background and objectives: Epidemiological studies suggest that coronavirus disease 2019 (COVID-19) has a less severe disease course and a more favorable prognosis among children. Childhood vaccines and heterologous immunity have been suggested as reasons for this. Additionally, the structural similarity between the measles, rubella, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus particles may affect immune responses. The objective of this study was to compare COVID-19 antibody titers and disease severity between measles-rubella (MR) vaccinated and unvaccinated children. Additionally, we aimed to evaluate and compare the antibody response in recipients of a single dose and two doses of the MR vaccine. Methods: The study was prospective and comparative and included 90 COVID-19-positive children aged nine months to 12 years. The study was registered under the clinical trials registry of India (CTRI/2021/01/030363). COVID-19 antibody titers were measured at two weeks, six weeks, and 12 weeks, along with the assessment of MR antibody titers. COVID-19 antibody titers and disease severity were compared between MR-vaccinated and MR-unvaccinated children. The comparison of COVID-19 antibody titers between recipients of a single dose and two doses of MR vaccine was also conducted. Results: The results showed significantly higher median COVID-19 antibody titers at all time points during follow-up in the MR-vaccinated group (P<0.05). However, the two groups had no significant difference in the disease severity. Moreover, there was no difference in the antibody titers of MR one dose and two dose recipients. Conclusion: Exposure to even a single dose of MR-containing vaccine enhances the antibody response against COVID-19. However, randomized trials are necessary to further explore this subject.
- 29 May 2023
- Published by Springer Nature in Cureus
- Vol. 15 (5) , e39671
Open AccessSerological Response to COVID-19 and Its Association With Measles-Rubella (MR)-Containing Vaccines
Background and objectives: Epidemiological studies suggest that coronavirus disease 2019 (COVID-19) has a less severe disease course and a more favorable prognosis among children. Childhood vaccines and heterologous immunity have been suggested as reasons for this. Additionally, the structural similarity between the measles, rubella, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus particles may affect immune responses. The objective of this study was to compare COVID-19 antibody titers and disease severity between measles-rubella (MR) vaccinated and unvaccinated children. Additionally, we aimed to evaluate and compare the antibody response in recipients of a single dose and two doses of the MR vaccine. Methods: The study was prospective and comparative and included 90 COVID-19-positive children aged nine months to 12 years. The study was registered under the clinical trials registry of India (CTRI/2021/01/030363). COVID-19 antibody titers were measured at two weeks, six weeks, and 12 weeks, along with the assessment of MR antibody titers. COVID-19 antibody titers and disease severity were compared between MR-vaccinated and MR-unvaccinated children. The comparison of COVID-19 antibody titers between recipients of a single dose and two doses of MR vaccine was also conducted. Results: The results showed significantly higher median COVID-19 antibody titers at all time points during follow-up in the MR-vaccinated group (P<0.05). However, the two groups had no significant difference in the disease severity. Moreover, there was no difference in the antibody titers of MR one dose and two dose recipients. Conclusion: Exposure to even a single dose of MR-containing vaccine enhances the antibody response against COVID-19. However, randomized trials are necessary to further explore this subject.
- Open Access
- 3 August 2022
- Published by Springer Nature in BMC Pediatrics
- Vol. 22 (1) , 1-8
Oral lactase for infantile colic: a randomized double-blind placebo-controlled trial
Background: Infantile colic is a common problem during the first three months of life. This randomized, double-blind, placebo-controlled trial conducted in an urban hospital in Delhi, India evaluated the efficacy and safety of oral lactase in management of infantile colic.Methods: One hundred sixty-two clinically healthy infants aged < 5 months age [mean (SD) = 63.5 (30.5) days] fulfilling the Rome-IV diagnostic criteria for infantile colic were enrolled. Eligible children were randomly allocated to receive 5 drops of lactase (600 FCC units/mL) (n = 80) or placebo (n = 82) mixed with breast milk or formula feed four times a day for a duration of 4 weeks. Primary outcomes were duration of crying or fussing (min/d), and number of days with colic lasting > 3 h/d; secondary outcomes were parental satisfaction and adverse events.Results: At the end of four weeks, mean (SD) crying or fussing time (min/d) was significantly shorter in infants receiving lactase in comparison to placebo [89.9 (115.2)vs.178.5 (153.2);P = 0.001]. The mean (SD) number of days with colic was also significantly less in the lactase group as compared to placebo group at the end of the treatment [12.1 (7.8)vs17.6 (8.4);P < 0.001]. By the end of 4thweek, parental satisfaction in terms of infant’s mood, activity, alertness, comfort and oral intake was better in intervention group. The adverse event profile was comparable between two groups.Conclusions: Oral lactase treatment in infantile colic results in symptomatic relief in terms of shortening of duration of crying or fussing, and better parental satisfaction.Trial registration: Clinical trial registry of India (CTRI/2017/12/010930) registered on 20/12/2017.
- 3 August 2022
- Published by Springer Nature in BMC Pediatrics
- Vol. 22 (1) , 1-8
Open AccessOral lactase for infantile colic: a randomized double-blind placebo-controlled trial
Background: Infantile colic is a common problem during the first three months of life. This randomized, double-blind, placebo-controlled trial conducted in an urban hospital in Delhi, India evaluated the efficacy and safety of oral lactase in management of infantile colic.Methods: One hundred sixty-two clinically healthy infants aged < 5 months age [mean (SD) = 63.5 (30.5) days] fulfilling the Rome-IV diagnostic criteria for infantile colic were enrolled. Eligible children were randomly allocated to receive 5 drops of lactase (600 FCC units/mL) (n = 80) or placebo (n = 82) mixed with breast milk or formula feed four times a day for a duration of 4 weeks. Primary outcomes were duration of crying or fussing (min/d), and number of days with colic lasting > 3 h/d; secondary outcomes were parental satisfaction and adverse events.Results: At the end of four weeks, mean (SD) crying or fussing time (min/d) was significantly shorter in infants receiving lactase in comparison to placebo [89.9 (115.2)vs.178.5 (153.2);P = 0.001]. The mean (SD) number of days with colic was also significantly less in the lactase group as compared to placebo group at the end of the treatment [12.1 (7.8)vs17.6 (8.4);P < 0.001]. By the end of 4thweek, parental satisfaction in terms of infant’s mood, activity, alertness, comfort and oral intake was better in intervention group. The adverse event profile was comparable between two groups.Conclusions: Oral lactase treatment in infantile colic results in symptomatic relief in terms of shortening of duration of crying or fussing, and better parental satisfaction.Trial registration: Clinical trial registry of India (CTRI/2017/12/010930) registered on 20/12/2017.
- 1 January 2022
- Published by Discover STM Publishing Ltd. in Sudanese Journal of Paediatrics
- Vol. 22 (1) , 10-18
Measles, mumps, and rubella (MMR) vaccine and heterologous immunity: a way out of the COVID-19 crisis?
Heterologous immunity is a well-known concept in immunology wherein prior exposure to an antigen confers cross protection against an unrelated antigen. With the surge in global COVID-19 cases, there has been significant research into the application of vaccine induced heterologous immunity associated with measles, mumps, and rubella (MMR) vaccine, Bacillus Calmette–Guerin (BCG) vaccine, oral polio vaccine (OPV) and hepatitis A vaccine in curbing the worst outcomes of COVID-19 infection. Despite having specific vaccines against COVID-19, it is worthwhile exploring the application of available vaccines in the prevention of severe disease until the vaccines reach all sections of the population across the globe. In this article, we aim to outline the concept of heterologous immunity and its relevance in context to MMR vaccine and COVID-19.
- 1 January 2022
- Published by Discover STM Publishing Ltd. in Sudanese Journal of Paediatrics
- Vol. 22 (1) , 10-18
Measles, mumps, and rubella (MMR) vaccine and heterologous immunity: a way out of the COVID-19 crisis?
Heterologous immunity is a well-known concept in immunology wherein prior exposure to an antigen confers cross protection against an unrelated antigen. With the surge in global COVID-19 cases, there has been significant research into the application of vaccine induced heterologous immunity associated with measles, mumps, and rubella (MMR) vaccine, Bacillus Calmette–Guerin (BCG) vaccine, oral polio vaccine (OPV) and hepatitis A vaccine in curbing the worst outcomes of COVID-19 infection. Despite having specific vaccines against COVID-19, it is worthwhile exploring the application of available vaccines in the prevention of severe disease until the vaccines reach all sections of the population across the globe. In this article, we aim to outline the concept of heterologous immunity and its relevance in context to MMR vaccine and COVID-19.
- 15 May 2021
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 32 (5) , 443-450
Behavioral Intervention in Children with Functional Abdominal Pain Disorders: A Promising Option
Background: The objectives of this study were to identify and classify patients with functional abdominal pain disorders (FAPD) into its various subtypes as per the Rome IV criteria and to evaluate the underlying psychological factors and the effect of behavioral intervention in children with FAPD. Methods: A validated Questionnaire on Pediatric Gastrointestinal Symptoms (QPGS) based on Rome IV criteria was used to identify and classify children presenting with abdominal pain. The children diagnosed as having FAPD were referred for psychological screening to evaluate for underlying psychosocial problems. The scales namely Pediatric Anxiety Rating Scale (PARS), Depression self-rating scale (DSRS), and Visual Analog Scale (VAS) were administered to children to assess the response of the child to behavioral therapy. Results: Of 100 children, 32, 26, 22, and 20% of children belonged to the subtypes of functional abdominal pain—not otherwise specified, abdominal migraine, irritable bowel syndrome, and functional dyspepsia, respectively. The most common associated psychosocial factors were academic burden, poor financial condition, exam-related stress, and bullying at school. The influence of behavioral therapy was statistically significant (P < .05). The mean (±standard deviation) PARS and DSRS scores were significantly reduced at 3 months of follow-up. Discussion: The most common subtypes reported were functional abdominal pain—not otherwise specified and abdominal migraine. Psychological factors such as academic burden, poor financial condition, exam-related stress, and bullying at school need to be ruled out in children with this condition. Non-pharmacological intervention such as behavioral therapy can confer a remarkable improvement in the symptoms of children with FAPD.
- 15 May 2021
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 32 (5) , 443-450
Behavioral Intervention in Children with Functional Abdominal Pain Disorders: A Promising Option
Background: The objectives of this study were to identify and classify patients with functional abdominal pain disorders (FAPD) into its various subtypes as per the Rome IV criteria and to evaluate the underlying psychological factors and the effect of behavioral intervention in children with FAPD. Methods: A validated Questionnaire on Pediatric Gastrointestinal Symptoms (QPGS) based on Rome IV criteria was used to identify and classify children presenting with abdominal pain. The children diagnosed as having FAPD were referred for psychological screening to evaluate for underlying psychosocial problems. The scales namely Pediatric Anxiety Rating Scale (PARS), Depression self-rating scale (DSRS), and Visual Analog Scale (VAS) were administered to children to assess the response of the child to behavioral therapy. Results: Of 100 children, 32, 26, 22, and 20% of children belonged to the subtypes of functional abdominal pain—not otherwise specified, abdominal migraine, irritable bowel syndrome, and functional dyspepsia, respectively. The most common associated psychosocial factors were academic burden, poor financial condition, exam-related stress, and bullying at school. The influence of behavioral therapy was statistically significant (P < .05). The mean (±standard deviation) PARS and DSRS scores were significantly reduced at 3 months of follow-up. Discussion: The most common subtypes reported were functional abdominal pain—not otherwise specified and abdominal migraine. Psychological factors such as academic burden, poor financial condition, exam-related stress, and bullying at school need to be ruled out in children with this condition. Non-pharmacological intervention such as behavioral therapy can confer a remarkable improvement in the symptoms of children with FAPD.